Titan Medical Inc. Research and Development Expense
Titan Medical Inc. reported Research and Development Expense of $7.61 million for the 3-month period ending 2022-09-30, per its 6-K filed 2022-11-10.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2022-11-10
- Titan Medical Inc. research and development expense for the quarter ending 2022-09-30 was $7.61M, a 28.95% decline year-over-year.
- Titan Medical Inc. research and development expense for the quarter ending 2022-06-30 was $9.51M, a 13.73% increase year-over-year.
- Titan Medical Inc. research and development expense for the quarter ending 2022-03-31 was $9.43M, a 23.40% increase year-over-year.
- Titan Medical Inc. research and development expense for the quarter ending 2021-12-31 was $9.60M, a 74.40% increase year-over-year.
| Period end | Research And Development Expense 3 month | Research And Development Expense 3 month as first filed | Research And Development Expense 6 month | Research And Development Expense 6 month as first filed | Research And Development Expense 9 month | Research And Development Expense 9 month as first filed | Research And Development Expense 12 month | Research And Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-09-30 | $7.61M 6-K · filed 2022-11-10 | $17.12M derived: sum of 2 quarters · filed 2022-11-10 | $26.72M 6-K · filed 2022-11-10 | $36.15M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2022-06-30 | $9.51M 6-K · filed 2022-08-11 | $19.11M 6-K · filed 2022-08-11 | $28.53M derived: sum of 3 quarters · filed 2022-08-11 | $39.25M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2022-03-31 | $9.43M 6-K · filed 2022-05-12 | $19.02M derived: sum of 2 quarters · filed 2022-05-12 | $29.74M derived: sum of 3 quarters · filed 2022-11-10 | $38.10M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-12-31 | $9.60M derived: 20-F 12 month − 6-K 9 month · filed 2022-03-24 | $20.31M derived: sum of 2 quarters · filed 2022-11-10 | $28.67M derived: sum of 3 quarters · filed 2022-11-10 | $37.95M 20-F · filed 2022-03-24 | ||||
| 2021-09-30 | $10.71M 6-K · filed 2022-11-10 | $10.59M 6-K · filed 2021-11-12 | $19.07M derived: sum of 2 quarters · filed 2022-11-10 | $28.36M 6-K · filed 2022-11-10 | $27.15M 6-K · filed 2021-11-12 | $32.22M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $8.36M 6-K · filed 2022-08-11 | $7.09M 6-K · filed 2021-08-11 | $17.64M 6-K · filed 2022-08-11 | $14.73M 6-K · filed 2021-08-11 | $21.50M derived: sum of 3 quarters · filed 2022-08-11 | $23.77M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $7.64M 6-K · filed 2022-05-12 | $13.14M derived: sum of 2 quarters · filed 2022-05-12 | $15.41M derived: sum of 3 quarters · filed 2022-05-12 | $15.53M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $5.50M derived: 20-F 12 month − 6-K 9 month · filed 2022-03-24 | $7.77M derived: sum of 2 quarters · filed 2022-03-24 | $7.89M derived: sum of 3 quarters · filed 2022-03-24 | $7.94M 20-F · filed 2022-03-24 | $7.94M 6-K · filed 2021-02-22 | |||
| 2020-09-30 | $2.27M 6-K · filed 2021-11-12 | $2.27M 6-K · filed 2020-11-16 | $2.39M derived: sum of 2 quarters · filed 2021-11-12 | $2.43M 6-K · filed 2021-11-12 | $2.43M 6-K · filed 2020-11-16 | $4.51M derived: sum of 4 quarters · filed 2022-03-24 | ||
| 2020-06-30 | $121.00K 6-K · filed 2021-08-11 | $121.46K 6-K · filed 2020-08-12 | $168.00K 6-K · filed 2021-08-11 | $167.58K 6-K · filed 2020-08-12 | $2.25M derived: sum of 3 quarters · filed 2022-03-24 | $18.82M derived: sum of 4 quarters · filed 2022-03-24 | ||
| 2020-03-31 | $46.00K 6-K · filed 2021-05-17 | $2.12M derived: sum of 2 quarters · filed 2022-03-24 | $18.69M derived: sum of 3 quarters · filed 2022-03-24 | $37.06M derived: sum of 4 quarters · filed 2022-03-24 | ||||
| 2019-12-31 | $2.08M derived: 20-F 12 month − 6-K 9 month · filed 2022-03-24 | $18.65M derived: sum of 2 quarters · filed 2022-03-24 | $37.01M derived: sum of 3 quarters · filed 2022-03-24 | $51.42M 20-F · filed 2022-03-24 | $51.42M 20-F · filed 2020-04-02 | |||
| 2019-09-30 | $16.57M 6-K · filed 2020-11-16 | $34.93M derived: sum of 2 quarters · filed 2020-11-16 | $49.34M 6-K · filed 2020-11-16 | |||||
| 2019-06-30 | $18.36M 6-K · filed 2020-08-12 | $32.77M 6-K · filed 2020-08-12 | ||||||
| 2018-12-31 | $14.19M derived: 20-F 12 month − 6-K 9 month · filed 2020-04-02 | $23.34M derived: sum of 2 quarters · filed 2020-04-02 | $29.58M derived: sum of 3 quarters · filed 2020-04-02 | $32.86M 20-F · filed 2020-04-02 | ||||
| 2018-09-30 | $9.14M 6-K · filed 2019-11-15 | $15.39M derived: sum of 2 quarters · filed 2019-11-15 | $18.66M 6-K · filed 2019-11-15 | |||||
| 2018-06-30 | $6.25M 6-K/A · filed 2019-09-30 | $9.52M 6-K/A · filed 2019-09-30 | ||||||
| 2017-12-31 | $12.90M 20-F/A · filed 2020-04-02 |